Products
Loading...

ERBB2

More+
ERBB2 (also known as NEU, CD340) is a 185 kDa cell membrane receptor encoded by the proto-oncogene ERBB-2, which is one of the members of the epidermal growth factor receptor (EGFR) family. The amplification or overexpression of this oncogene has already shown an important role in the development and progression of certain invasive types of breast cancer. In recent years, this protein has become an important biomarker and therapeutic target for about 30% of breast cancer patients. The Ras-MAPK and PI3K-Akt signal transduction activity in ERBB2 high expression tumor cells was higher, cell proliferation ability was stronger, differentiation and apoptosis mechanisms were inhibited, and the degree of cell malignancy was high. ERBB2 high expression of tumor cells can resist the effects of TNF-α, radiation and various chemotherapy drugs caused by apoptosis. Clinically, ERBB2 expression is closely related to the prognosis of patients. Patients with high expression of ErbB2 are prone to tumor metastasis and have a short survival period. Due to the significant difference in the expression level of ERBB2 in normal cells and tumor cells, it has become an ideal target for tumor immunological therapy, and is also a hotspot in the field of tumor therapy research. Trastuzumab is a monoclonal antibody used to treat breast cancer. Specifically for breast cancer that is positive for ERBB2 receptors, it can be used alone or in combination with other chemotherapy drugs. Trastuzumab is given by slow infusion into the vein and injection under the skin.

Derivation:
Humanized (from mouse)
Species Reactivity:
Human
Type:
IgG1 - kappa
Application:
ELISA, IP, FC, FuncS, Neut, IF, ICC
Derivation:
Humanized (from mouse)
Species Reactivity:
Human
Type:
IgG1 - kappa
Application:
FuncS, IF, Neut, ELISA, FC, IP, WB
Derivation:
Humanized (from mouse)
Species Reactivity:
Human
Type:
Humanized (from mouse) IgG1 - kappa
Application:
IP, IF, FuncS, FC, Neut, ELISA, WB
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Application:
Cytotoxicity assay, Function study
Species Reactivity:
Human
Type:
Llama VHH
Application:
IHC, FC, CA, FuncS
Species Reactivity:
human
Type:
scFv-(D-Arg)9
Application:
IF, FC, FuncS
Species Reactivity:
human
Type:
scFv-(+36GFP)
Application:
WB, ICC, FuncS
Species Reactivity:
human
Type:
scFv-Tat
Application:
ICC, Neut, FuncS
Target:
Her-2 receptor
Linker:
2, 4 or 6 Phor18 molecules
Target:
HER2
Drug:
Gly5-modified DM1 (Gly5-modified N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
Target:
HER2
Linker:
VC-PAB (valine-citrulline-p-aminobenzoyloxycarbonyl)
Drug:
MMAE (Monomethyl auristatin E)
Target:
HER2
Linker:
MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)
Drug:
MMAF (Monomethyl auristatin F)
Target:
HER2
Linker:
Mc (maleimidocaproyl)
Drug:
MMAF (Monomethyl auristatin F)
Target:
HER2
Linker:
BMPEO (bis-maleimido-trioxyethylene glycol)
Drug:
DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)